Acarbose
- Generic Name
- Acarbose
- Brand Names
- Precose
- Drug Type
- Small Molecule
- Chemical Formula
- C25H43NO18
- CAS Number
- 56180-94-0
- Unique Ingredient Identifier
- T58MSI464G
- Background
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex...
- Indication
Acarbose is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
- Conditions
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- University Hospital, Gentofte, Copenhagen
- Target Recruit Count
- 15
- Registration Number
- NCT03241303
- Locations
- 🇩🇰
Center for Diabetesresearch, Hellerup, Denmark
Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Peking University
- Target Recruit Count
- 100
- Registration Number
- NCT02999841
- Locations
- 🇨🇳
Beijing Pinggu Hospital, Beijing, Beijing, China
Study of Acarbose in Longevity
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT02953093
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Acarbose Anti-aging Effects in Geriatric Subjects (Substudy B & C)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2019-03-14
- Target Recruit Count
- 8
- Registration Number
- NCT02865499
- Locations
- 🇺🇸
UTHSCSA, San Antonio, Texas, United States
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
- Conditions
- Interventions
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 892
- Registration Number
- NCT02836704
Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia
- Conditions
- Interventions
- First Posted Date
- 2016-02-19
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 11
- Registration Number
- NCT02685852
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2015-11-18
- Target Recruit Count
- 100
- Registration Number
- NCT02605772
Human Oral Detection of Glucose Olygomers
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oregon State University
- Target Recruit Count
- 157
- Registration Number
- NCT02589353
- Locations
- 🇺🇸
Department of Food Science and Technology, Corvallis, Oregon, United States
Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2015-07-16
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT02500329
- Locations
- 🇰🇷
Boramae medical center, Seoul, Korea, Republic of
Research of Intensive Lifestyle Intervention for PCOS Patients With IGT
- Conditions
- Interventions
- First Posted Date
- 2015-05-18
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT02446834
- Locations
- 🇨🇳
Renji Hospital Department of Endocrinology and Metabolism, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.